Home » Acambis’ ACAM2000 Vaccine for Protection Against Smallpox
Acambis’ ACAM2000 Vaccine for Protection Against Smallpox
Acambis said that the FDA has approved its smallpox vaccine, ACAM2000 for persons at high risk for smallpox infection.
Acambis developed ACAM2000 under contracts with the Centers for Disease Control and Prevention (CDC) as part of its preparations for a public health emergency.
The company said it has supplied 192.5 million doses of ACAM2000 for the U.S. government’s strategic national stockpile.
Acambis is currently in advanced negotiations with the CDC for a warm-base manufacturing contract to provide long-term ACAM2000 production capability that is located entirely in the U.S.
Upcoming Events
-
07May
-
14May
-
30May